H.C. Wainwright

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe. This year's meeting is is scheduled for May 29-31 and is organized as a virtual event due to the...

Despite Inovio Pharmaceuticals Inc's (NASDAQ: INO) first-quarter miss Monday, the sell-side remains largely upbeat on company, which is developing a coronavirus vaccine candidate.  The Inovio Analysts Stifel analyst Stephen Wiley maintained a Buy rating and $19 price target for Inovio...

Novavax, Inc. (NASDAQ: NVAX) announced Monday after the close an award of an incremental $384 million in funding by the Coalition for Epidemic Preparedness Innovations alongside forecast-beating first-quarter results. The Novavax Analysts H.C. Wainwright analyst Vernon Bernardino reiterated a Buy...

Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thursday after a second bidder emerged. Two-way Race The Watertown, Massachusetts-based company, which has a...

Coronavirus vaccine play Inovio Pharmaceuticals Inc (NASDAQ: INO) announced the completion of enrollment in the Phase 1 trial of its COVID-19 DNA vaccine INO-4800 and positive Phase 1/2a data for its MERS coronavirus vaccine INO-4700 on Tuesday. The Inovio Analysts Cantor Fitzgerald analyst...

The COVID-19 virus has sent the market and the global economy into a tailspin. The Organisation for Economic Co-operation and Development slashed its global growth forecast for 2020 Monday by 0.5 points to 2.5% versus already-weak 2.9% growth in 2019. Global banks have begun talking up the...

Christmas came early for Amarin Corporation plc (NASDAQ: AMRN) with the FDA's approval of an expanded label for its fish oil pill Vascepa ahead of a scheduled Dec. 28 decision date.  The label expansion approved Friday includes the indication of cardiovascular risk reduction in...

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Following Biogen Inc's (NASDAQ: BIIB) presentation of detailed top-line results for aducanumab at the Alzheimer's conference, the stock ended Thursday's session up about 3.5%. The presentation polarized analysts and clinicians alike, stirring a debate on whether the data is sufficient...

Immunomedics, Inc. (NASDAQ: IMMU) is a biopharma company focusing on the development of antibody-drug conjugates, or ADCs. The Morris Plains, New Jersey-based company was founded in 1982 and has yet to market a commercial product.  Its investigational therapies include ADCs that are...

Vericel Corp (NASDAQ: VCEL), a commercial-stage company that specializes in advanced cell therapies for treating patients with knee cartilage defects and severe burn wounds, is investment-worthy, according to H.C. Wainwright. The Analyst Analyst Swayampakula Ramakanth initiated coverage of...

The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is set to present at the European Association for the Study of Diabetes 55th annual meeting with results from the Part...

Aimmune Therapeutics Inc (NASDAQ: AIMT)'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. Following the positive verdict, H.C. Wainwright looked at what the decision means...

Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares, which suffered a setback in late February following the release of the FDA's briefing document and panel vote on its multiple myeloma treatment candidate Selinexor, were seeing upward momentum on double their average volume Friday. What...

Biogen Inc (NASDAQ: BIIB) announced Monday a deal to buy gene therapy biotech Nightstar Therapeutics PLC (NASDAQ: NITE) for $800 million. The Analysts Baird analyst Brian Skorney maintained a Neutral rating on Biogen with a $348 price target. H.C. Wainwright analyst Andrew Fein reiterated a Buy...